IN THE MATTER OF the Patent Act R.S.C. 1985, c. P-4,
as amended
AND IN THE MATTER OF Alexion Pharmaceuticals Inc.
(the “Respondent”) and the medicine “Soliris”

TAKE NOTICE that the Patented Medicine Prices Review Board (the “Board”) will hold a hearing in its offices in the Standard Life Centre, 333 Laurier Avenue West, 18th Floor, Ottawa, Ontario, on a date to be determined by the Hearing Panel no later than March 6, 2015.

The purpose of the hearing is to determine whether, under sections 83 and 85 of the Patent Act, the Respondent is selling or has sold the medicine known as Soliris in any market in Canada at a price that, in the Board’s opinion, is or was excessive and if so, what order, if any, should be made.

Soliris is the first and only treatment for patients with Paroxysmal Nocturnal Hemoglobinuria (“PNH”). PNH is a rare and life-threatening blood disorder that is characterized by complement-mediated hemolysis (the destruction of red blood cells).

Soliris is also approved as the first and only treatment for patients with atypical hemolytic uremic syndrome (aHUS). aHUS is a rare and life-threatening genetic disorder characterized by “complement-mediated thrombotic microangiopathy”, or TMA (blood clots in small vessels). Soliris is indicated to inhibit complement-mediated TMA.

Persons wishing to intervene in the proceeding are required to apply to the Board for leave to intervene. Such persons should contact the Secretary of the Board for further information on the procedure.

All requests for information should be addressed to the Secretary of the Board: Guillaume Couillard, Standard Life Centre, Suite 1400, 333 Laurier Avenue West, Ottawa, Ontario K1P 1C1; 1 877 861-2350 (Toll-free number); (613) 954-8299 (Direct line); (613) 952-7626 (Facsimile); (E-mail).

Date modified: